Cite
HARVARD Citation
Denmeade, S. et al. (n.d.). A phase II study of rapid cycling high dose testosterone (Bipolar Androgen Therapy) in men with metastatic castrate-resistant prostate cancer (mCRPC) resistant to abiraterone and/or enzalutamide. European journal of cancer. pp. S15-. [Online].